Common Contracts
7 similar Employment Agreement contracts by Voyager Therapeutics, Inc.
EMPLOYMENT AGREEMENTEmployment Agreement • June 13th, 2024 • Voyager Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (this “Agreement”) is made as of July 8, 2024 (the “Effective Date”) by and between (i) Voyager Therapeutics, Inc., a Delaware corporation with an address at 75 Hayden Avenue, Lexington, MA 02421 (the “Company”) and (ii) Nathan Jorgensen, Ph.D., MBA, an individual with an address at [**] (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • March 13th, 2024 • Voyager Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (this “Agreement”) is made as of February 29, 2024 (the “Effective Date”) by and between Voyager Therapeutics, Inc. (the “Company”) and Toby Ferguson, M.D., Ph.D. (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • July 10th, 2023 • Voyager Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (this “Agreement”) is made as of July 5, 2023 (the “Effective Date”) by and between Voyager Therapeutics, Inc. (the “Company”) and Jacquelyn Fahey Sandell (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • September 7th, 2022 • Voyager Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (this “Agreement”) is made as of September 7, 2022 (the “Effective Date”) by and between Voyager Therapeutics, Inc. (the “Company”) and Peter Pfreundschuh (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • November 7th, 2018 • Voyager Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (the “Agreement”) is made effective as of November 7, 2018 (the “Effective Date”) by and between Voyager Therapeutics, Inc. (the “Company”) and Allison Dorval (the “Executive”). Except with respect to the Executive’s Confidentiality, Noncompetition and Assignment Agreement with the Company (the “Confidentiality Agreement”) dated May 18, 2017 between the Company and the Executive, the Company’s 2015 Stock Option and Grant Plan and any applicable stock option and/or restricted stock agreements with the Company with respect to equity grants held by the Executive (collectively, the “Equity Documents”), this Agreement supersedes, amends and restates in all respects all prior agreements and understandings between the Executive and the Company regarding the subject matter herein, including without limitation the May 17, 2017 offer letter entered into by the Executive and the Company (the “Offer Letter”).
EMPLOYMENT AGREEMENTEmployment Agreement • September 18th, 2017 • Voyager Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (the “Agreement”) is made effective as of September 11, 2017 (the “Effective Date”) by and between Voyager Therapeutics, Inc. (the “Company”) and Matthew P. Ottmer, (the “Executive”). Except with respect to the Executive’s Confidentiality, Noncompetition and Assignment Agreement with the Company (the “Employee Agreement”) between the Company and the Executive, the Company’s 2015 Stock Option and Grant Plan and any applicable stock option and/or restricted stock agreements with the Company with respect to equity grants held by the Executive (collectively, the “Equity Documents”), this Agreement supersedes, amends and restates in all respects all prior agreements and understandings between the Executive and the Company regarding the subject matter herein, including without limitation the September 1, 2017 offer letter, and any previous offer letters, provided to the Executive by the Company (the “Prior Offer Letter”).
EMPLOYMENT AGREEMENTEmployment Agreement • January 3rd, 2017 • Voyager Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (the “Agreement”) is made effective as of January 1, 2017 (the “Effective Date”) by and between Voyager Therapeutics, Inc. (the “Company”) and Jane Pritchett Henderson (the “Executive”). Except with respect to the Executive’s Confidentiality, Noncompetition and Assignment Agreement with the Company (the “Employee Agreement”) between the Company and the Executive, the Company’s 2014 Stock Option and Grant Plan and any applicable stock option and/or restricted stock agreements with the Company with respect to equity grants held by the Executive (collectively, the “Equity Documents,”) this Agreement supersedes, amends and restates in all respects all prior agreements and understandings between the Executive and the Company regarding the subject matter herein, including without limitation the December 18, 2016 offer letter provided to the Executive by the Company (the “Prior Offer Letter”).
